BACKGROUND AND PURPOSE: Vascular prevention trials mostly count "yes/no" (binary) outcome events, eg, stroke/no stroke. Analysis of ordered categorical vascular events (eg, fatal stroke/nonfatal stroke/no stroke) is clinically relevant and could be more powerful statistically. Although this is not a novel idea in the statistical community, ordinal outcomes have not been applied to stroke prevention trials in the past. METHODS: Summary data on stroke, myocardial infarction, combined vascular events, and bleeding were obtained by treatment group from published vascular prevention trials. Data were analyzed using 10 statistical approaches which allow comparison of 2 ordinal or binary treatment groups. The results for each statistical test for ...
Objective: To compare how 3 common representations (ordinal vs dichotomized as 0–1/2–6 or 0–2/3–6) o...
Objective – To compare how three common representations (ordinal versus dichotomized as 0-1/2-6 or 0...
Cardiovascular outcomes trials (CVOTs) with novel drugs to treat type 2 diabetes have uniformly chos...
Background and Purpose—Vascular prevention trials mostly count “yes/no” (binary) outcome events, eg,...
Abstract Background Vascular prevention trials typically use dichotomous event outcomes although thi...
Background: Ordinalised vascular outcomes incorporating event severity are more informative than bin...
The online version of this article, along with updated information and services, is located on th
Background: Many acute stroke trials have given neutral results. Sub-optimal statistical analyses ma...
Most large acute stroke trials have shown no treatment effect. Functional outcome is routinely used ...
Background Many acute stroke trials have given neutral results. Sub-optimal statistical analyses ma...
Background: There is a growing interest in assessment of the quality of hospital care, based on outc...
Background and Purpose— Most large acute stroke trials have been neutral. Functional outcome is usua...
textabstractIntroduction: In clinical trials, ordinal outcome measures are often dichotomized into t...
BACKGROUND AND PURPOSE: Most large acute stroke trials have been neutral. Functional outcome is usua...
Background and purpose: Arguments persist as to whether parametric or nonparametric methods should b...
Objective: To compare how 3 common representations (ordinal vs dichotomized as 0–1/2–6 or 0–2/3–6) o...
Objective – To compare how three common representations (ordinal versus dichotomized as 0-1/2-6 or 0...
Cardiovascular outcomes trials (CVOTs) with novel drugs to treat type 2 diabetes have uniformly chos...
Background and Purpose—Vascular prevention trials mostly count “yes/no” (binary) outcome events, eg,...
Abstract Background Vascular prevention trials typically use dichotomous event outcomes although thi...
Background: Ordinalised vascular outcomes incorporating event severity are more informative than bin...
The online version of this article, along with updated information and services, is located on th
Background: Many acute stroke trials have given neutral results. Sub-optimal statistical analyses ma...
Most large acute stroke trials have shown no treatment effect. Functional outcome is routinely used ...
Background Many acute stroke trials have given neutral results. Sub-optimal statistical analyses ma...
Background: There is a growing interest in assessment of the quality of hospital care, based on outc...
Background and Purpose— Most large acute stroke trials have been neutral. Functional outcome is usua...
textabstractIntroduction: In clinical trials, ordinal outcome measures are often dichotomized into t...
BACKGROUND AND PURPOSE: Most large acute stroke trials have been neutral. Functional outcome is usua...
Background and purpose: Arguments persist as to whether parametric or nonparametric methods should b...
Objective: To compare how 3 common representations (ordinal vs dichotomized as 0–1/2–6 or 0–2/3–6) o...
Objective – To compare how three common representations (ordinal versus dichotomized as 0-1/2-6 or 0...
Cardiovascular outcomes trials (CVOTs) with novel drugs to treat type 2 diabetes have uniformly chos...